Combination of dacarbazine and mitomycin in advanced colorectal cancer

Summary Twenty evaluable patients with advanced measurable colorectal cancer received 3-week courses of a combination of IV dacarbazine 300 mg/m²/day from day 1 to day 5 and IV mitomycin 2 mg/m²/day from day 1 to day 5. Fourteen of these patients had had no prior chemotherapy and received two or more courses of this two-drug regimen. None of the patients achieved complete or partial response. Severe to life-threatening myelosuppression, was encountered in patients with prior radiotherapy and or prior chemotherapy, and/or in patients with a Karnofsky score 70. Hematologic toxicity was mild in the other patients. Nonhematologic toxic effects were generally mild to moderate and consisted essentially in nausea and vomiting. It is concluded that in our hands the regimen selected for this trial has no significant antitumor activity in advanced colorectal cancer.     

Cerebrospinal fluid cyclic AMP and acid monoamine metabolites following probenecid: Studies in psychiatric patients

At probenecid levels greater than 10 g/ml, CSF cAMP was independent of CSF probenecid concentration. At these levels of probenecid, cAMP transport out of CSF is probably maximally blocked and cAMP levels reflect cAMP release into CSF. CSF cAMP was significantly higher in RDC-diagnosed schizophrenics than in other psychotics or depressives. A significant decrease in CSF cAMP was found in psychotic patients treated with chlorpromazine. No changes in CSF cAMP were observed in patients treated with tricyclic antidepressants or lithium.     

High-dose immunoglobulin therapy for Guillain−Barré syndrome in Japanese children

BACKGROUND: Guillain-Barré syndrome (GBS) is an acute acquired demyelinating polyneuropathy, presumed to be immune-mediated. Intravenous immunoglobulin (IVIg) has been used to treat GBS and was found to be effective. However, a well-controlled study of pediatric GBS has not been conducted in Japan. Therefore, to evaluate the efficacy of IVIg in the treatment of GBS, an open-labeled study was performed in pediatric patients. METHODS: Participants in the study were required to be younger than 15 years old, and diagnosed as having moderate or severe GBS. IVIg (400 mg/kg per day) was administered to patients for five consecutive days. Predefined outcome measures were defined on a seven-point scale of motor function (Hughes' functional grade [FG]). RESULTS: Eleven patients were treated with IVIg. The median time taken to improve by one grade on the FG scale was 10.0 days after initial treatment. Two weeks after initial treatment, 72.7% of patients treated with IVIg improved by one or more grades, and 36.4% improved by two or more grades, measured on the FG scale. After 4 weeks an improvement by one or more grades was observed in 81.8% of patients, and two or more grades in 63.6% of patients. These improvement rates were markedly greater than would occur with the natural course of GBS1. Adverse events (subjective symptoms or abnormal laboratory findings) were observed in four patients, although all were temporary and mild. CONCLUSIONS: The authors conclude that IVIg is a safe and effective treatment for childhood GBS, which shortens the time to recovery.     

股骨头缺血性坏死的介入治疗

目的 探讨介入治疗股骨头缺血性坏死的临床效果。方法 对13例16髋股骨头缺血性坏死．经患髋的旋股内、外动脉或闭孔动脉灌注溶栓药物及血管扩张药物等。结果 随访3～6个月．髋关节疼痛消失6髋，减轻8髋；功能恢复5髋，功能改善8髋。结论 介入治疗股骨头缺血性坏死，能改善股骨头血液循环，能有效地改善临床症状和髋关节的活动功能，其创伤小且安全可靠。     

大黄蒽醌含量测定方法的研究

目的：测定大黄中游离蒽醌和总蒽醚的含量。方法：采用甲醇冷浸法，利用蒽醌衍生物在碱性条件下呈红色的特点，用可见分光光度法测定其含量。结果：该法测定平均回收率为100．2％，RSD＝2．96％(n＝5)，线性范围为5μg一30μg，r＝0．9999。结论：用本法检测大黄中的蒽醌含量，方法简便，结果可靠。     

盐酸特拉唑嗪胶囊的稳定性研究

目的：考察盐酸特拉唑嗪胶囊的稳定性。方法：通过影响因素(强光照射、高温、高温)，加速和留样考察实验，以含量为测定指标，考察胶囊的含量变化。结果：在温度40℃、60℃、光照3500LX及RH75％等因素影响下，胶囊的含量无明显变化。结论：在25℃时，通过经典恒温加速试验推测盐酸特拉唑嗪胶囊的失效期为2年。     

阿佐塞米合成工艺的研究

目的：对阿佐塞米合成工艺进行研究。方法：以2-氟-4-氯苯甲酸为起始原料合成阿佐塞米粗品用80％乙醇加活性炭脱色重结晶在60℃以下真空干燥后所得白色结晶性粉末阿佐塞米。结果：总收率为22％，mp：222．7与文献接近。结论：以此工艺合成阿佐塞米是可行的。     

青霉素过滤工艺改进

目的：为了进一步解决青霉素生产过过程中的过滤问题和进一步扩大产量，克服原设备的缺陷。方法：我们采用了目前国内制药企业广泛使用的鼓式过滤机过滤技术及利用热交换器进行热量交换以达到生产工艺的要求同时改进相应工艺。结果：达到降低生产成本、扩大生产产量、加快生产速度，提高生产产率的结果。结论：通过实际生产证明完全符合实际生产的需要。本文就目前青霉素过滤过程中的几个关键环节作简要讨论。